Acute respiratory distress syndrome and lung injury: Pathogenetic mechanism and therapeutic implication
- PMID: 24701402
- PMCID: PMC3953859
- DOI: 10.5492/wjccm.v1.i2.50
Acute respiratory distress syndrome and lung injury: Pathogenetic mechanism and therapeutic implication
Abstract
To review possible mechanisms and therapeutics for acute lung injury (ALI) and acute respiratory distress syndrome (ARDS). ALI/ARDS causes high mortality. The risk factors include head injury, intracranial disorders, sepsis, infections and others. Investigations have indicated the detrimental role of nitric oxide (NO) through the inducible NO synthase (iNOS). The possible therapeutic regimen includes extracorporeal membrane oxygenation, prone position, fluid and hemodynamic management and permissive hypercapnic acidosis etc. Other pharmacological treatments are anti-inflammatory and/or antimicrobial agents, inhalation of NO, glucocorticoids, surfactant therapy and agents facilitating lung water resolution and ion transports. β-adrenergic agonists are able to accelerate lung fluid and ion removal and to stimulate surfactant secretion. In conscious rats, regular exercise training alleviates the endotoxin-induced ALI. Propofol and N-acetylcysteine exert protective effect on the ALI induced by endotoxin. Insulin possesses anti-inflammatory effect. Pentobarbital is capable of reducing the endotoxin-induced ALI. In addition, nicotinamide or niacinamide abrogates the ALI caused by ischemia/reperfusion or endotoxemia. This review includes historical retrospective of ALI/ARDS, the neurogenic pulmonary edema due to head injury, the detrimental role of NO, the risk factors, and the possible pathogenetic mechanisms as well as therapeutic regimen for ALI/ARDS.
Keywords: Acute lung injury; Acute respiratory distress syndrome; Inducible nitric oxide synthase; Nitric oxide; Pathogenetic mechanisms; Therapeutic regimen.
Figures
Similar articles
-
Acute lung injury and acute respiratory distress syndrome: experimental and clinical investigations.J Geriatr Cardiol. 2011 Mar;8(1):44-54. doi: 10.3724/SP.J.1263.2011.00044. J Geriatr Cardiol. 2011. PMID: 22783284 Free PMC article.
-
ONO-1714, a nitric oxide synthase inhibitor, attenuates endotoxin-induced acute lung injury in rabbits.Anesth Analg. 2003 Dec;97(6):1751-1755. doi: 10.1213/01.ANE.0000086896.90343.13. Anesth Analg. 2003. PMID: 14633554
-
Delivery systems of therapeutic nucleic acids for the treatment of acute lung injury/acute respiratory distress syndrome.J Control Release. 2023 Aug;360:1-14. doi: 10.1016/j.jconrel.2023.06.018. Epub 2023 Jun 19. J Control Release. 2023. PMID: 37330013 Review.
-
Protective effects of propofol on acute lung injury induced by oleic acid in conscious rats.Crit Care Med. 2008 Apr;36(4):1214-21. doi: 10.1097/CCM.0b013e31816a0607. Crit Care Med. 2008. PMID: 18379248
-
From neurogenic pulmonary edema to fat embolism syndrome: a brief review of experimental and clinical investigations of acute lung injury and acute respiratory distress syndrome.Chin J Physiol. 2009 Nov 30;52(5 Suppl):339-44. doi: 10.4077/cjp.2009.amh036. Chin J Physiol. 2009. PMID: 20359124 Review.
Cited by
-
Ulinastatin post-treatment attenuates lipopolysaccharide-induced acute lung injury in rats and human alveolar epithelial cells.Int J Mol Med. 2017 Feb;39(2):297-306. doi: 10.3892/ijmm.2016.2828. Epub 2016 Dec 13. Int J Mol Med. 2017. PMID: 27959396 Free PMC article.
-
Protection of toll-like receptor 9 against lipopolysaccharide-induced inflammation and oxidative stress of pulmonary epithelial cells via MyD88-mediated pathways.Physiol Res. 2022 Apr 30;71(2):259-273. doi: 10.33549/physiolres.934741. Epub 2022 Apr 11. Physiol Res. 2022. PMID: 35275698 Free PMC article.
-
Attenuation of Lipopolysaccharide-Induced Acute Lung Injury by Cyclosporine-A via Suppression of Mitochondrial DNA.Med Sci Monit. 2018 Oct 27;24:7682-7688. doi: 10.12659/MSM.909909. Med Sci Monit. 2018. PMID: 30367813 Free PMC article.
-
Endotoxin-Induced Sepsis on Ceftriaxone-Treated Rats' Ventilatory Mechanics and Pharmacokinetics.Antibiotics (Basel). 2024 Jan 15;13(1):83. doi: 10.3390/antibiotics13010083. Antibiotics (Basel). 2024. PMID: 38247642 Free PMC article.
-
First Evidence of the Protective Effects of 2-Pentadecyl-2-Oxazoline (PEA-OXA) in In Vitro Models of Acute Lung Injury.Biomolecules. 2022 Dec 24;13(1):33. doi: 10.3390/biom13010033. Biomolecules. 2022. PMID: 36671418 Free PMC article.
References
-
- Ware LB, Matthay MA. The acute respiratory distress syndrome. N Engl J Med. 2000;342:1334–1349. - PubMed
-
- Vincent JL, Sakr Y, Ranieri VM. Epidemiology and outcome of acute respiratory failure in intensive care unit patients. Crit Care Med. 2003;31:S296–S299. - PubMed
-
- Ksiazek TG, Erdman D, Goldsmith CS, Zaki SR, Peret T, Emery S, Tong S, Urbani C, Comer JA, Lim W, et al. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med. 2003;348:1953–1966. - PubMed
-
- Drosten C, Günther S, Preiser W, van der Werf S, Brodt HR, Becker S, Rabenau H, Panning M, Kolesnikova L, Fouchier RA, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med. 2003;348:1967–1976. - PubMed
Publication types
LinkOut - more resources
Full Text Sources